Edwards Lifesciences Corporatio (EW) Stock Analysis
Healthcare · Medical Devices
Sell if holding. At $81.54, A.R:R 1.4:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Leverage penalty (D/E 6.8): -1.5; Thin upside margin: 7.5%.
Edwards Lifesciences is a global medical device company focused on structural heart therapies, including TAVR (SAPIEN valve family), transcatheter mitral and tricuspid therapies (TMTT), and surgical structural heart products. Revenue is earned from worldwide hospital and... Read more
Sell if holding. At $81.54, A.R:R 1.4:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Leverage penalty (D/E 6.8): -1.5; Thin upside margin: 7.5%. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.7/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, no SEC red flags, news boost analyst 0.70, earnings proximity 84d clear, semi cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
10 dimensions · all in-band
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $81.54, A.R:R 1.4:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Leverage penalty (D/E 6.8): -1.5; Thin upside margin: 7.5%. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $76.89. Score 5.7/10, moderate confidence.
Take-profit target: $87.43 (+7.5% upside). Prior stop was $76.89. Stop-loss: $76.89.
Thin upside margin: 7.5%; Leverage penalty (D/E 6.8): -1.5; Consecutive earnings misses (2).
Edwards Lifesciences Corporatio trades at a P/E of 43.9 (forward 24.1). TrendMatrix value score: 4.2/10. Verdict: Sell.
43 analysts cover EW with a consensus score of 4.0/5. Average price target: $97.
What does Edwards Lifesciences Corporatio do?Edwards Lifesciences is a global medical device company focused on structural heart therapies, including TAVR (SAPIEN...
Edwards Lifesciences is a global medical device company focused on structural heart therapies, including TAVR (SAPIEN valve family), transcatheter mitral and tricuspid therapies (TMTT), and surgical structural heart products. Revenue is earned from worldwide hospital and physician sales; it sold its Critical Care segment to Becton, Dickinson and Company in September 2024.